Membranous Nephropathy(MN) Test Kit

Membranous nephropathy (MN) presents as an organ-specific autoimmune disease. PLA2R, C1q and THSD7A can be used to guide the diagnosis, prognosis and disease monitoring of MN.

Products Details

Chemiluminescent Solution(Autoimmune Diseases)


Product Name


Membranous Nephropathy

Anti-Phospholipase A2 Receptor Antibody


Anti-C1q Antibody


Anti-thrombospondin Type I Domain Containing 7A Antibody


Membranous nephropathy (MN) presents as an organ-specific autoimmune disease. Phospholipase A2 receptors (PLA2R), belonging to type I transmembrane receptor, are expressed by glomerular cell surface. In patients of membranous nephropathy with phospholipase A2 receptor antibody-positive, circulating anti-phospholipase A2 receptor antibody and antigen to phospholipase A2 receptors conjugate as an immune complex, deposit on the glomerular basement membrane, activate the complement system which ultimately damages Sertoli cell and the glomerular filtration barrier and causing urine protein. The level of PLA2R is closely related to clinical activity, which is a good indicator to predict the disease process. Analysis showed that the serum PLA2R level was with a sensitivity of 73% and specificity of 83% for the diagnosis of active idiopathic membranous nephropathy, indicating that serum PLA2R level has diagnostic value in the active stage of idiopathic membranous nephropathy. C1q is a component of complement 1(C1), the initiator of the classical pathway of innate immune complement. C1q acts as the first reaction subunit of the first component of complement C1. It binds to antigen-antibody immune-complexes, participates in classical complement activation pathways together with C1r and C1s molecules, and mediates clearance of infectious factors, apoptotic products and immune complexes in the mononuclear macrophage system. When anti-C1Q antibodies exist, it will slow down the clearance of immune complex and apoptotic cells, stimulate the immune system to produce more antibodies, which is a factor leading to disease (systemic lupus erythematosus) activity. Type Ⅰ platelet reactive protein 7A domain (THSD7A) is another podocyte antigen that causes MN after phospholipase A2 receptor (PLA2R). The discovery of THSD7A and its antibodies led to a new understanding of MN. Serum THSD7A antibody can bind to podocyte THSD7A antigen to form in situ immune complex, leading to podocyte injury and proteinuria. Similar to PLA2R antibody, THSD7A antibody can be used to guide the diagnosis, prognosis and disease monitoring of MN.  

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours